CRTX — CRISM Therapeutics Income Statement
0.000.00%
Last trade - 00:00- £4.40m
- £2.53m
Annual income statement for CRISM Therapeutics, fiscal year end - December 31st, GBP millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | fx Final | fx Final | fx Final | fx Final | fx Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 1.55 | 2.49 | 1.3 | 2.11 | 1.82 |
| Operating Profit | -1.55 | -2.49 | -1.3 | -2.11 | -1.82 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -1.83 | -2.08 | -1.3 | -2.11 | -1.92 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -1.83 | -2.08 | -1.3 | -2.11 | -1.92 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -1.83 | -2.08 | -0.877 | -2.45 | -7.76 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -1.83 | -2.08 | -0.877 | -2.45 | -7.76 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.397 | -0.273 | -0.128 | -0.208 | -0.221 |
| Special Dividends per Share |